AbbVie scores dual EU approvals for Rinvoq in vitiligo, alopecia on July 30, 2026 AbbVie Adolescent (age group) Adult Alopecia Approved CHMP EU European Commission approval older Opinions Positive Rinvoq Severe (severity modifier) systemic treatment upadacitinib Vitiligo +
Tenpoint Therapeutics Submits MAA for YUVEZZI to MHRA for Presbyopia Treatment in Adults on July 14, 2026 Adult brimonidine BRIO I BRIO II carbachol Eye Drops Healthcare products International Recognition Procedure Marketing Authorization MHRA Phase 3 trials presbyopia regulatory agency Tenpoint Therapeutics YUVEZZI +
Satellos Shares Early Adult Data for Duchenne Pill Ahead of Key Pediatric Readout on July 09, 2026 Adult Hand Strength Muscular Dystrophy, Duchenne oral pill Phase 2 TRAILHEAD SAT-3247 Satellos United States Food and Drug Administration Vital capacity test +
CHMP Recommends Moderna's mCombriax Flu-COVID Vaccine for Adults 50+ on March 02, 2026 Adult CHMP COVID19 (disease) Influenza mCombriax Moderna Multiple Acyl Coenzyme A Dehydrogenase Deficiency Vaccines +
FDA Broadens COVID-19 Vaccine Safety Probe to Adults Under New Health Leadership on December 10, 2025 Adult COVID19 (disease) Moderna Myocarditis Pfizer public trust safety review United States Food and Drug Administration vaccine deaths Vaccines +
FDA Approves Novartis' Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients on November 25, 2025 Adult Approved gene therapy intrathecal formulation Itvisma Novartis older children Spinal Muscular Atrophy United States Food and Drug Administration Zolgensma +
Moderna Wins Expanded FDA Approval for RSV Vaccine in At-Risk Younger Adults on June 13, 2025 Adult Approved at-risk chronic health conditions expanded label Moderna mRESVIA RSV vaccine United States Food and Drug Administration +
Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring on April 30, 2025 Access Adult CALR gene LifeMD Nordisk Obesity semaglutide Telemedicine Wegovy +
CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s on April 16, 2025 50–59 Adult Age Arexvy broaden Centers for Disease Control and Prevention (U.S.) Chronic Condition Recommendation Respiratory syncytial virus Severe (severity modifier) Vaccines +
Entrada given go-ahead to test DMD therapy after two-year hold on February 25, 2025 Adult DMD Duchenne Entrada Exons Muscular Dystrophy United States Food and Drug Administration +